Overview
Balance Sheet
Cash Flow
Growth Analysis
2024
2023
2022
2021
2020
Profitability Metrics
Gross Margin
91.47%
Operating Margin
119.64%
Net Margin
99.41%
Efficiency Metrics
Revenue per Expense Ratio
10.97
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
119.64%
Income Tax Rate
0.00%
EPS
1.6600000000
Balance Sheet Analysis
Current Ratio
8,466,005.0
Cash Ratio
8,466,005.0
Working Capital
$8.47M
Debt to Equity
0.27
Debt to Assets
21.11%
Equity Ratio
77.84%
Cash Flow Analysis
Operating Cash Flow Ratio
78.36%
Free Cash Flow Ratio
78.36%
CapEx to Revenue
0.00%
Dividends Paid
$51.56M
Stock Buybacks
No buybacks
Total Shareholder Returns
$51.56M
Cash Position Change
36.55%
Key Takeaways (2024 FY)
Maintained positive net income growth despite revenue changes
Detailed Growth Metrics
Core Performance
Revenue
91.39%
Net Income
93.82%
EPS
93.02%
Operating Income
133.25%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
2.24%
Operating Cash Flow
1,656.82%
Free Cash Flow
1,656.82%
Balance Sheet Health
Assets
3.06%
Debt
0.00%
Book Value per Share
3.14%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
0.00%
Shares Outstanding
0.00%
Long Term Trends
3Y Revenue/Share
-32.90%
5Y Revenue/Share
6.59%
3Y Dividend/Share
0.03%
5Y Dividend/Share
16.91%